Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

1.

Oncogenically active MYD88 mutations in human lymphoma.

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM.

Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.

PMID:
21179087
[PubMed - indexed for MEDLINE]
2.

Modulation of Toll-interleukin 1 receptor mediated signaling.

Li X, Qin J.

J Mol Med (Berl). 2005 Apr;83(4):258-66. Epub 2005 Jan 21. Review.

PMID:
15662540
[PubMed - indexed for MEDLINE]
3.

The biology of human lymphoid malignancies revealed by gene expression profiling.

Staudt LM, Dave S.

Adv Immunol. 2005;87:163-208. Review.

PMID:
16102574
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Molecular pathology of lymphoma.

Coupland SE.

Eye (Lond). 2013 Feb;27(2):180-9. doi: 10.1038/eye.2012.247. Epub 2012 Dec 7. Review.

PMID:
23222560
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?

Barton S, Hawkes EA, Wotherspoon A, Cunningham D.

Oncologist. 2012;17(12):1562-73. doi: 10.1634/theoncologist.2012-0218. Epub 2012 Oct 18. Review.

PMID:
23086691
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma.

Hill BT, Sweetenham J.

Leuk Lymphoma. 2012 May;53(5):763-9. doi: 10.3109/10428194.2011.626882. Epub 2012 Jan 5. Review.

PMID:
21992676
[PubMed - indexed for MEDLINE]
7.

Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large B-cell lymphoma: a review of the literature.

Tirado CA, Chen W, García R, Kohlman KA, Rao N.

J Hematol Oncol. 2012 Sep 11;5:54. doi: 10.1186/1756-8722-5-54. Review.

PMID:
22967872
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.

Lim KH, Yang Y, Staudt LM.

Immunol Rev. 2012 Mar;246(1):359-78. doi: 10.1111/j.1600-065X.2012.01105.x. Review.

PMID:
22435566
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The STIR-domain superfamily in signal transduction, development and immunity.

Novatchkova M, Leibbrandt A, Werzowa J, Neubüser A, Eisenhaber F.

Trends Biochem Sci. 2003 May;28(5):226-9. Review.

PMID:
12765832
[PubMed - indexed for MEDLINE]
10.

Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency.

Picard C, Casanova JL, Puel A.

Clin Microbiol Rev. 2011 Jul;24(3):490-7. doi: 10.1128/CMR.00001-11. Review.

PMID:
21734245
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Targeting the Toll-like receptor/interleukin 1 receptor pathway in human diseases: rational design of MyD88 inhibitors.

Loiarro M, Ruggiero V, Sette C.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):222-6. doi: 10.1016/j.clml.2013.02.003. Epub 2013 Mar 13. Review.

PMID:
23490990
[PubMed - indexed for MEDLINE]
12.

Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma.

Puvvada S, Kendrick S, Rimsza L.

Cancer Genet. 2013 Jul-Aug;206(7-8):257-65. doi: 10.1016/j.cancergen.2013.07.003. Epub 2013 Sep 27. Review.

PMID:
24080457
[PubMed - indexed for MEDLINE]
13.

Diffuse large B cell lymphoma: molecular targeted therapy.

Roschewski M, Dunleavy K, Wilson WH.

Int J Hematol. 2012 Nov;96(5):552-61. doi: 10.1007/s12185-012-1198-3. Epub 2012 Oct 20. Review.

PMID:
23086603
[PubMed - indexed for MEDLINE]
14.

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

Parekh S, Privé G, Melnick A.

Leuk Lymphoma. 2008 May;49(5):874-82. doi: 10.1080/10428190801895345. Review.

PMID:
18452090
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Targeting TLR/IL-1R signalling in human diseases.

Loiarro M, Ruggiero V, Sette C.

Mediators Inflamm. 2010;2010:674363. doi: 10.1155/2010/674363. Epub 2010 Apr 8. Review.

PMID:
20396389
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia.

Poulain S, Herbaux C, Bertrand E, Decambron A, Fouquet G, Boyle E, Gay J, Manier S, Duthilleul P, Roumier C, Leleu X.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):202-4. doi: 10.1016/j.clml.2013.02.008. Epub 2013 Mar 7. Review.

PMID:
23473949
[PubMed - indexed for MEDLINE]
17.

Janus kinase deregulation in leukemia and lymphoma.

Chen E, Staudt LM, Green AR.

Immunity. 2012 Apr 20;36(4):529-41. doi: 10.1016/j.immuni.2012.03.017. Review.

PMID:
22520846
[PubMed - indexed for MEDLINE]
Free Article
18.

II. Therapy of DLBCL based on genomics.

Staudt LM.

Hematol Oncol. 2013 Jun;31 Suppl 1:26-8. doi: 10.1002/hon.2062. Review. No abstract available.

PMID:
23775644
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk